600267.SHG Zhejiang Hisun Pharmaceutical Co Ltd
- Market cap
- CNY 16.1B
- P/E
- 12.4x
- P/B
- 1.58x
- ROE
- 16.1%
- Dividend yield
- 2.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600267.SHG undervalued?
Graham number600267.SHG trades 6.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Hisun Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Hisun Pharmaceutical Co Ltd yet.
Zhejiang Hisun Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others. The company exports its products to approx…
Full company profileZhejiang Hisun Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Hisun Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.73B | 10.6B | 10.2B | 11.1B | 11.4B | 12.1B | 12.0B | 10.4B | 9.79B | 10.5B | 8.69B |
| Gross Profit | 2.62B | 3.26B | 4.18B | 4.43B | 4.81B | 4.81B | 4.92B | 4.04B | 4.14B | 4.73B | 5.08B |
| Operating Income | 12.2M | 249M | -103M | 521M | 777M | 700M | 682M | 89.4M | 721M | 1.28B | 1.81B |
| EBITDA | 834M | 1.17B | 925M | 398M | 1.85B | 1.80B | 1.99B | 1.35B | 1.71B | 1.89B | 1.92B |
| Net Income | -94.4M | 13.6M | -492M | 93.1M | 417M | 487M | 489M | -93.2M | 601M | 541M | 1.53B |
| EPS | -0.10 | 0.01 | -0.51 | 0.10 | 0.43 | 0.43 | 0.42 | -0.08 | 0.52 | 0.45 | 1.29 |
| Balance Sheet | |||||||||||
| Total Assets | 20.8B | 21.6B | 21.9B | 21.5B | 20.9B | 19.4B | 18.8B | 17.6B | 16.0B | 15.1B | 13.8B |
| Total Liabilities | 12.7B | 13.8B | 14.5B | 13.8B | 12.6B | 12.0B | 10.4B | 9.26B | 7.39B | 6.20B | 4.04B |
| Shareholders' Equity | 6.76B | 6.72B | 6.18B | 6.27B | 6.68B | 7.30B | 8.08B | 8.10B | 8.34B | 8.61B | 9.51B |
| Cash & Short-term Investments | 2.69B | 2.31B | 1.89B | 1.76B | 2.06B | 1.30B | 1.40B | 1.59B | 1.50B | 1.29B | 1.18B |
| Total Debt | 10.1B | 10.7B | 10.7B | 8.87B | 8.17B | 7.63B | 6.13B | 4.55B | 3.23B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 776M | 1.24B | 1.45B | 698M | 1.59B | 1.74B | 2.07B | 1.52B | 2.11B | 2.03B | - |
| Capital Expenditure | 1.77B | 1.46B | 1.60B | 1.08B | 692M | 622M | 531M | 240M | 238M | 376M | 456M |
| Free Cash Flow | -991M | -221M | -155M | -378M | 898M | 1.11B | 1.54B | 1.26B | 1.88B | 1.66B | 1.15B |
| Ratios | |||||||||||
| ROE | -1.4% | 0.2% | -8.0% | 1.5% | 6.2% | 6.7% | 6.1% | -1.1% | 7.2% | 6.3% | 16.1% |
| ROA | -0.5% | 0.1% | -2.3% | 0.4% | 2.0% | 2.5% | 2.6% | -0.5% | 3.8% | 3.6% | 11.1% |
| Net Profit Margin | -1.0% | 0.1% | -4.8% | 0.8% | 3.7% | 4.0% | 4.1% | -0.9% | 6.1% | 5.1% | 17.6% |
| Debt to Equity | 1.50x | 1.59x | 1.73x | 1.41x | 1.22x | 1.04x | 0.76x | 0.56x | 0.39x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Hisun Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.13%
- Forward dividend
- 0.21 CNY
- Payout ratio
- 63.5%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 343M | 0.29 | 63.5% |
| 2024 | CNY 148M | 0.13 | 24.7% |
| 2023 | CNY 199M | 0.17 | - |
| 2022 | CNY 166M | 0.14 | 34.0% |
| 2021 | CNY 58.0M | 0.05 | 11.9% |
| 2020 | CNY 48.2M | 0.05 | 11.6% |
| 2019 | CNY 499M | 0.52 | 536.5% |
| 2018 | CNY 538M | 0.56 | - |
| 2017 | CNY 524M | 0.55 | 3,865.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 16:10 on May 25, 2012.
Who owns Zhejiang Hisun Pharmaceutical Co Ltd
- Insiders 44.84%
- Institutions 2.25%
- Public & others 52.91%
- Shares outstanding 1.18B
- Free float 704M
Zhejiang Hisun Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Hisun Pharmaceutical Co Ltd
- Ticker
- 600267.SHG
- ISIN
- CNE0000013Z2
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jul 5, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 8,751
- Fiscal year end
- December
- Address
- No. 46, Waisha Road, Taizhou, China, 318000
- Phone
- 86 576 8882 7890
- Website
- hisunpharm.com
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others. The company exports its products to approximately 70 countries worldwide. Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 1956 and is headquartered in Taizhou, China.
Zhejiang Hisun Pharmaceutical Co Ltd management
6- Mr. Weihong XiaoCEO & Chairman · born 1969
- Mr. Ling JiangSenior VP, Accounting Supervisor & CFO · born 1971
- Mr. Hong Shun JinSenior Vice President · born 1976
- Mr. Zhiqing YangSenior Vice President · born 1975
- Mr. Jiaqiu DuSenior VP & Director · born 1974
- Ms. Qianbo ZhaoBoard Secretary · born 1982